Get started
Author

Megan Ann McNamara

Observed names: M.A. McNamara, Megan A McNamara, Megan A. McNamara, Megan McNamara
Observed institutions: Cleveland Clinic, University of California, Los Angeles, Duke University, Louis Stokes Cleveland VA Medical Center, Duke Medical Center, Durham VA Medical Center, Duke Cancer Institute, Case Western Reserve University
ORCID: 0000-0002-7324-3199
Observed ORCID: 0000-0002-7324-3199
OpenAlex ID: A5005547611
RNA-Based Vaccines in Cancer Immunotherapy
2015 · Megan A. McNamara, Smita K. Nair, et al. · Journal of Immunology Research · 229
PDF
Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models
2016 · Eda K. Holl, Michael C. Brown, et al. · Oncotarget · 73
PDF
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer
2019 · Robert B. Den, Daniel George, et al. · American Journal of Clinical Oncology · 59
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
2021 · Tian Zhang, Anika Agarwal, et al. · Biomarker Research · 53
PDF
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer
2021 · Daniel J. George, Susan Halabi, et al. · Cancer · 45
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
2019 · Matthew K. Labriola, Kristen A. Batich, et al. · Clinical Genitourinary Cancer · 41
Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).
2018 · Daniel J. George, Elisabeth I. Heath, et al. · Journal of Clinical Oncology · 37
Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
2019 · Megan Ann McNamara, Daniel J. George, et al. · Journal of Clinical Oncology · 35
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation
2017 · Megan McNamara, Christopher Sweeney, et al. · Prostate Cancer and Prostatic Diseases · 32
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report
2015 · Megan A McNamara, Daniel J George · BMC Cancer · 31
PDF
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
2019 · Eda K. Holl, Megan A. McNamara, et al. · Prostate Cancer and Prostatic Diseases · 26
PDF
Platinum sensitivity in metastatic prostate cancer: does histology matter?
2017 · Michael S. Humeniuk, Rajan T. Gupta, et al. · Prostate Cancer and Prostatic Diseases · 26
A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects
2023 · Zev M. Nakamura, Allison M. Deal, et al. · Cancer Medicine · 24
PDF
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND)
2022 · Michael R. Harrison, Paul G. Davis, et al. · Prostate Cancer and Prostatic Diseases · 24
Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer
2019 · Jason Zhu, Matthew Tucker, et al. · Urologic Oncology Seminars and Original Investigations · 24
Incidence of prostate cancer in transgender women in the US: a large database analysis
2024 · Matthew Loria, David Gilbert, et al. · Prostate Cancer and Prostatic Diseases · 18
PDF
Serum Testosterone to Androstenedione Ratio Predicts Metabolic Health in Normal-Weight Polycystic Ovary Syndrome Women
2021 · Daniel A Dumesic, Ayli Tulberg, et al. · Journal of the Endocrine Society · 18
The burden of chronic pain in transgender and gender diverse populations: Evidence from a large US clinical database
2024 · Tomasz Tabernacki, David Gilbert, et al. · European Journal of Pain · 16
PDF
The impact of gender-affirming interventions on eating disorder diagnosis risk among transgender and gender-diverse individuals
2024 · Matthew Loria, Tomasz Tabernacki, et al. · Communications Medicine · 8
PDF
Cancer of the Kidney
2020 · Megan A. McNamara, Tian Zhang, et al. · Elsevier eBooks · 7
Patterns of response and progression in bone and soft tissue during and after treatment with radium‐223 for metastatic castrate‐resistant prostate cancer
2019 · Megan Ann McNamara, Taofik Oyekunle, et al. · The Prostate · 7
A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder
2019 · Chester Kao, Megan McNamara, et al. · Clinical Genitourinary Cancer · 7
Rates of Urinary Tract Infection in Transgender Women Postvaginoplasty vs Cisgender Women: A Retrospective Cohort Study in a Large US Health Network
2024 · David Gilbert, Aishwarya Gautam, et al. · Urology · 5
PDF
PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).
2019 · Michael Roger Harrison, Michel Khouri, et al. · Journal of Clinical Oncology · 3
Immune checkpoint inhibitor response in tumors with LRP1B variants.
2019 · Jason Zhu, Matthew D Tucker, et al. · Journal of Clinical Oncology · 2
Works count: 46
Citation count: 862
H-index: 17
I10-index: 18
Year
Topic
Type